Key facts, as of
As of October 7, 2026, Quest Diagnostics (DGX) trades at $228.39, up 28.0% over the past year. Its 52-week range runs from $171.18 to $248.84; the price is 8.2% below that high. It is 8.2% below its all-time high of $248.84, reached in September 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +234.0%, against +312.9% for the S&P 500 (SPY). It sits 10.6% above its 200-day average of $206.59, the usual sign of a long-term uptrend. Its 30-day volatility is 26.0% annualized, which we rate medium risk. It has a trailing P/E of 24.2 and a dividend yield of 1.51%.
Cite: Portfolio Terminal, "Quest Diagnostics (DGX) stock analysis", 2026-10-07. https://portfolio-terminal.com/analyse/dgx
Where it trades today
trading 74% of the way up its 52-week range
How the price has moved
How far it is from its record
Quest Diagnostics (DGX) is 8.2% below its all-time high of $248.84, reached in September 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +234.0%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- DGX is valued near its sector range at 24.2x earnings versus 22.0x for peers, so the next move likely needs a real earnings or guidance catalyst.
- DGX carries a beta of 0.54, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- DGX is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in DGX.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for DGX come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for DGX. Last refresh: Oct 7, 2026, 9:55 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Quest Diagnostics does
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service…
Employees
46,000
Industry
Diagnostics & Research
Headquarters
Secaucus, United States
What analysts expect
DGX carries a buy consensus from 15 analysts, with an average price target of $248.07 versus $228.39 today (+8.6%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
DGX generated $11.56B in trailing revenue (10.2% year over year), with a 9.2% net margin, and $909.63M of free cash flow, against $5.78B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $11.04B | $3.67B | $1.56B | $992.00M | $8.87 | $1.36B |
| 2024 | $9.87B | $3.24B | $1.35B | $871.00M | $7.78 | $909.00M |
| 2023 | $9.25B | $3.05B | $1.26B | $854.00M | $7.59 | $864.00M |
| 2022 | $9.88B | $3.43B | $1.43B | $946.00M | $8.10 | $1.31B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
DGX is in 8 of the 30 ETFs we track. It weighs most in XLV: 0.42% of the fund, holding #44 of 62.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
DGX beside the healthcare names it is usually measured against.
What the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 4.0% below its 50-day average and 10.6% above its 200-day.
- RSI at 39 is neither stretched nor washed out.
- The nearest ceiling is $248.01 (+8.6%), the nearest floor $213.35 (-6.6%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is DGX a good investment in 2026?
Quest Diagnostics trades at a P/E ratio of 24.2, with medium volatility (26.0% annualized). The stock is in a consolidation phase.
What is the risk level of DGX?
Based on 30-day volatility of 26.0%, DGX has MEDIUM risk. Beta of 0.54 indicates lower sensitivity to market movements than average.
Does DGX pay dividends?
Yes, Quest Diagnostics has a dividend yield of 1.51%.
How far is DGX from its all-time high?
Quest Diagnostics is 8.2% below its all-time high of $248.84, reached in September 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +234.0%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold DGX?
8 of the 30 popular ETFs we track hold Quest Diagnostics. The largest weights: XLV (0.42%), VIG (0.11%), VYM (0.11%), VTV (0.10%) and VOO (0.04%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is DGX?
0.04%, as of August 31, 2026: DGX is holding #334 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.40 in Quest Diagnostics.
What is the analyst price target for DGX?
The average analyst price target for Quest Diagnostics (DGX) is $248.07 based on 15 analyst estimates, about 8.6% above the current price of $228.39. The published range runs from $204.00 to $265.00.
How much revenue does DGX generate?
Quest Diagnostics reported $11.56B in trailing twelve-month revenue. Revenue growth is running at 10.2% year over year. Net margin sits at 9.2%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare DGX with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.